Pemphigus vulgaris treatment is no longer a one-drug story. A review published by EMJ charts how therapeutic options for this rare, potentially fatal autoimmune blistering disease are moving beyond rituximab, the anti-CD20 monoclonal antibody that has anchored first-line care in recent years.

The pivot matters clinically. Pemphigus vulgaris is the most common form of pemphigus, driven by autoantibodies against desmoglein 3, with or without desmoglein 1 involvement. Untreated, widespread mucocutaneous blistering and erosions carry significant morbidity and historically high mortality. Long-term systemic corticosteroids changed that prognosis, but at the cost of serious adverse events, and the field has spent decades searching for steroid-sparing alternatives with better safety profiles.

What does the rituximab era leave unsolved?

Rituximab established that B-cell depletion can induce durable remission in pemphigus vulgaris, and it reshaped treatment guidelines accordingly. Yet clinicians who manage these patients know the gaps: not every patient achieves remission, responses can be delayed, relapse occurs despite maintenance dosing, and infusion reactions and infection risk complicate use in a population already vulnerable to immunosuppression-related complications.

Those limitations created the commercial and scientific rationale for the next wave of candidates. The EMJ review situates current pipeline activity in that context — a field that has validated its target biology through rituximab and now seeks agents with faster onset, improved tolerability, or more convenient administration.

Which mechanisms are in play?

The expansion beyond rituximab spans several mechanistic directions:

• Targeted B-cell depletion. Newer anti-CD20 agents and engineered antibodies aim to improve on rituximab's efficacy-to-safety ratio.
• Antibody-directed approaches. Because pemphigus vulgaris is antibody-mediated, therapies that accelerate clearance of pathogenic IgG or blunt plasma-cell output address the disease upstream of tissue damage.
• Immunomodulatory pathways. Agents repurposed from other autoimmune indications are being evaluated for their capacity to reduce blister formation while sparing patients cumulative steroid burden.

The review frames these developments not as a replacement for rituximab but as a broadening of the toolkit — a shift from a near-monoculture in advanced therapy toward a differentiated treatment landscape where mechanism and patient profile can be matched.

Why does this matter for dermatology practice?

Pemphigus vulgaris sits squarely in dermatology's territory, and most patients with the disease are diagnosed and longitudinally managed by dermatologists, often alongside rheumatology or internal medicine colleagues. Every new approved option changes the practical calculus of care: monitoring burden, infusion logistics, infection prophylaxis considerations, and the pace at which corticosteroids can be tapered.

For a rare disease, the arrival of multiple pipeline candidates also signals something larger — regulatory and commercial interest in autoimmune blistering diseases, a category that long relied on treatments borrowed from oncology and transplantation medicine. Orphan-drug development in dermatology has historically lagged behind more prevalent conditions, and pemphigus is now a visible counterexample.

What should clinicians watch next?

The review's core message is that the treatment conversation in pemphigus vulgaris is becoming genuinely plural. Where rituximab once defined the ceiling of what targeted therapy could achieve, investigators and clinicians now have reason to discuss comparative efficacy, sequencing, and combination strategies — questions that only arise when a second and third generation of options becomes realistic.

As these candidates advance through clinical evaluation, dermatologists can expect the coming years to bring head-to-head data and guideline updates that will determine how firmly the field moves beyond its rituximab-first foundation.